Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2010 |
| End Date: | September 2013 |
Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)
This is a randomized Phase II, open label, multi-centre study evaluating the anti-tumor
activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in
patients with Smoldering Multiple Myeloma. Patients will receive 6 injections of IPH2101, at
the dose of 0.2 mg/kg or 2 mg/kg (according to their randomization). Patients will be
followed 6 months after treatment completion or until a KIR occupancy level < 30% (i.e if
the time required for KIR desaturation was > 6 months), whichever is longer.
We found this trial at
6
sites
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Click here to add this to my saved trials
Little Rock, Arkansas 72205
Click here to add this to my saved trials
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials